TMEM27 expression and clinical characteristics and survival in clear cell renal cell carcinoma

References

• Zhang H, Wada J, Hida K, et al. Collectrin, a collecting duct-specific transmembrane glycoprotein, is a novel homolog of ACE2 and is developmentally regulated in embryonic kidneys. J Biol Chem. 2001;276(20):17132–17139.
   PubMed Web of Science ®Google Scholar
• Chu PL, Gigliotti JC, Cechova S, et al. Renal collectrin protects against Salt-Sensitive hypertension and is downregulated by angiotensin II. J Am Soc Nephrol. 2017;28(6):1826–1837.
   PubMed Web of Science ®Google Scholar
• Malakauskas SM, Quan H, Fields TA, et al. Aminoaciduria and altered renal expression of luminal amino acid transporters in mice lacking novel gene collectrin. Am J Physiol Renal Physiol. 2007;292(2):F533–44.
   PubMed Web of Science ®Google Scholar
• Cechova S, Zeng Q, Billaud M, et al. Loss of collectrin, an angiotensin-converting enzyme 2 homolog, uncouples endothelial nitric oxide synthase and causes hypertension and vascular dysfunction. Circulation. 2013;128(16):1770–1780.
   PubMed Web of Science ®Google Scholar
• Kidney Fact Sheet. International Agency for Research on Cancer: the Global Cancer Observatory; 2020.
   Google Scholar
• Znaor A, Lortet-Tieulent J, Laversanne M, et al. International variations and trends in renal cell carcinoma incidence and mortality. Eur Urol. 2015;67(3):519–530.
   PubMed Web of Science ®Google Scholar
• Chow WH, Dong LM, Devesa SS. Epidemiology and risk factors for kidney cancer. Nat Rev Urol. 2010;7(5):245–257.
   PubMed Web of Science ®Google Scholar
• Uhlen M, Zhang C, Lee S, et al. A pathology atlas of the human cancer transcriptome. Science. 2017;357(6352):eaan2507.
   PubMed Web of Science ®Google Scholar
• Javorhazy A, Farkas N, Beothe T, et al. Lack of TMEM27 expression is associated with postoperative progression of clinically localized conventional renal cell carcinoma. J Cancer Res Clin Oncol. 2016;142(9):1947–1953.
   PubMed Web of Science ®Google Scholar
• Rioux-Leclercq N, Karakiewicz PI, Trinh QD, et al. Prognostic ability of simplified nuclear grading of renal cell carcinoma. Cancer. 2007;109(5):868–874.
   PubMed Web of Science ®Google Scholar
• Delahunt B, Cheville JC, Martignoni G, Members of the ISUP Renal Tumor Panel, et al. The international society of urological pathology (ISUP) grading system for renal cell carcinoma and other prognostic parameters. Am J Surg Pathol. 2013;37(10):1490–1504.
   PubMed Web of Science ®Google Scholar
• Bakouny Z, Braun DA, Shukla SA, et al. Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma. Nat Commun. 2021;12(1):808.
   PubMed Web of Science ®Google Scholar
• Lucarelli G, Loizzo D, Franzin R, et al. Metabolomic insights into pathophysiological mechanisms and biomarker discovery in clear cell renal cell carcinoma. Expert Rev Mol Diagn. 2019; 19(5):397–407.
   PubMed Web of Science ®Google Scholar
• Qi X, Li Q, Che X, et al. The uniqueness of clear cell renal cell carcinoma: summary of the process and abnormality of glucose metabolism and lipid metabolism in ccRCC [review. Front Oncol. 2021;11:727778.
   PubMed Web of Science ®Google Scholar
• Malakauskas SM, Kourany WM, Zhang XY, et al. Increased insulin sensitivity in mice lacking collectrin, a downstream target of HNF-1α. Mol Endocrinol. 2009;23(6):881–892.
   PubMedGoogle Scholar
• Faubert B, Solmonson A, DeBerardinis RJ. Metabolic reprogramming and cancer progression. Science. 2020;368(6487):eaaw5473.
   PubMed Web of Science ®Google Scholar
• di Meo NA, Loizzo D, Pandolfo SD, et al. Metabolomic approaches for detection and identification of biomarkers and altered pathways in bladder cancer. Int J Mol Sci. 2022;23(8):4173.
   Web of Science ®Google Scholar
• Ferro M, Katalin MO, Buonerba C, et al. Type 2 diabetes mellitus predicts worse outcomes in patients with high-grade T1 bladder cancer receiving bacillus Calmette-Guerin after transurethral resection of the bladder tumor. Urol Oncol. 2020;38(5):459–464.
   PubMed Web of Science ®Google Scholar
• Lucarelli G, Loizzo D, Ferro M, et al. Metabolomic profiling for the identification of novel diagnostic markers and therapeutic targets in prostate cancer: an update. Expert Rev Mol Diagn. 2019;19(5):377–387.
   PubMed Web of Science ®Google Scholar